Cargando…

Immune Checkpoint Inhibitors in Melanoma and HIV Infection

INTRODUCTION: Immunotherapy with immune checkpoint inhibitors increases the overall survival of patients with metastatic melanoma regardless of their oncogene addicted mutations. However, no data is available from clinical trials of effective therapies in subgroups of melanoma patients that carry ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marra, Antonio, Scognamiglio, Giosuè, Peluso, Ilaria, Botti, Gerardo, Fusciello, Celeste, Filippelli, Amelia, Ascierto, Paolo A., Pepe, Stefano, Sabbatino, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730951/ https://www.ncbi.nlm.nih.gov/pubmed/29290886 http://dx.doi.org/10.2174/1874613601711010091

Ejemplares similares

Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature
por: Sabbatino, Francesco, et al.
Publicado: (2018)

Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma
por: Sabbatino, Francesco, et al.
Publicado: (2020)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
por: Botti, Gerardo, et al.
Publicado: (2017)

The Ratio of GrzB(+) − FoxP3(+) over CD3(+) T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma
por: Scognamiglio, Giosuè, et al.
Publicado: (2021)

Increased HOX C13 expression in metastatic melanoma progression
por: Cantile, Monica, et al.
Publicado: (2012)

PD-L1 Dysregulation in COVID-19 Patients
por: Sabbatino, Francesco, et al.
Publicado: (2021)

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
por: Simeone, Ester, et al.
Publicado: (2021)

PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation
por: Sabbatino, Francesco, et al.
Publicado: (2014)

PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the Use of Tissue Micro Arrays
por: Botti, Gerardo, et al.
Publicado: (2016)

Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma
por: Sabbatino, Francesco, et al.
Publicado: (2020)

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor
por: Fontana, Flavia, et al.
Publicado: (2019)

BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas
por: Colombino, Maria, et al.
Publicado: (2019)

Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival
por: Panza, Elisabetta, et al.
Publicado: (2016)

LncRNA HOTAIR in Tumor Microenvironment: What Role?
por: Botti, Gerardo, et al.
Publicado: (2019)

MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
por: Motti, Maria Letizia, et al.
Publicado: (2020)

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma
por: Botti, Gerardo, et al.
Publicado: (2017)

Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients
por: Sabbatino, Francesco, et al.
Publicado: (2020)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2014)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2015)

Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients
por: Sabbatino, Francesco, et al.
Publicado: (2021)

Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma
por: Mozzillo, Nicola, et al.
Publicado: (2012)

Genetic alterations in main candidate genes during melanoma progression
por: Sini, Maria Cristina, et al.
Publicado: (2018)

Overexpression of Cell Cycle Progression Inhibitor Geminin is Associated with Tumor Stem-Like Phenotype of Triple-Negative Breast Cancer
por: Di Bonito, Maurizio, et al.
Publicado: (2012)

Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management
por: Sacco, Alessandra, et al.
Publicado: (2020)

Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients
por: Botti, Gerardo, et al.
Publicado: (2017)

Different Prognostic Role of Soluble PD-L1 in the Course of Severe and Non-Severe COVID-19
por: Sabbatino, Francesco, et al.
Publicado: (2023)

Characterization of respiratory infection viruses in hospitalized children from Naples province in Southern Italy
por: Botti, Chiara, et al.
Publicado: (2018)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

Posterior HOX genes and HOTAIR expression in the proximal and distal colon cancer pathogenesis
por: Tatangelo, Fabiana, et al.
Publicado: (2018)

Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumors
por: Cantile, Monica, et al.
Publicado: (2013)

Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors
por: Cristiani, Costanza Maria, et al.
Publicado: (2022)

No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
por: Guida, Michele, et al.
Publicado: (2021)

Concomitant Administration of Capecitabine and Folate Supplements: Need to Encourage Medication Reconciliation
por: Stefanelli, Berenice, et al.
Publicado: (2022)

New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors
por: Mozzillo, Nicola, et al.
Publicado: (2013)

Duodenal gangliocytic paraganglioma, a rare entity among GEP-NET: a case report with immunohistochemical and molecular study
por: Tatangelo, Fabiana, et al.
Publicado: (2014)

Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients
por: Carbone, Maria Luigia, et al.
Publicado: (2022)

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors
por: Costa Svedman, Fernanda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2s9e33cdcqnch547o7tcc7mnu2